Sarepta shares slump after report of patient death in early-stage study
July 18 (Reuters) - Shares of Sarepta Therapeutics SRPT.O declined 16.5% to $18.32 in premarket trading on Friday after a Bloomberg report that a patient enrolled in an early-stage study of one of the company's gene therapies has died from acute liver failure.
The latest death marks the third treatment-related fatality this year. Two teenage boys have died after receiving Sarepta's Elevidys, a gene therapy approved to treat a rare muscular dystrophy.
Sarepta did not immediately respond to a Reuters request for comment outside of its business hours.
The patient was enrolled in a study testing Sarepta's gene therapy to treat another muscle-wasting disorder called limb-girdle muscular dystrophy, according to the Bloomberg report, which cited a company spokesperson.
Related Articles
International Copper Prices Rise for 7 Straight Months; Will Bull Market Continue in 2026?
TradingKey - As the "king of industrial metals," every fluctuation in international copper prices impacts the nerves of global investors. In early 2026, international copper prices continued to rise, extending the upward trend from 2025 and reaching a new high above $14,500, marking seven consecutive months of gains. Meanwhile, London Metal Exchange (LME) copper prices have climbed from $7,800 per tonne in July 2025 to over $9,000 per tonne today.
Nikkei Index Heading Toward 60,000? Why Is Global Capital Betting on Sanae Takaichi? Will Japan’s Stock Market Continue to Hit New Highs in 2026?
TradingKey - In February 2026, the Tokyo stock market once again became the epicenter of global financial markets. Following a landslide victory by the Sanae Takaichi-led Liberal Democratic Party in the Lower House elections, the Nikkei 225 Index hit consecutive record highs within just a few days, targeting the 60,000-point milestone.
Is SaaS Dead? The Truth Behind the Software Meltdown, the Missing Floor, and the Peak That’s Not Coming Back
TradingKey - A trillion dollars just vanished from software stocks—this piece breaks down who AI is really killing, who quietly benefits, and why cheap SaaS may be the biggest value trap of this cycle.
USD Dollar Trend Forecast: Dollar Index Falls Below 97.0 to 4-Year Low, Will the Dollar Continue To Fall or Bottom Out in 2026?
TradingKey - In January 2026, the US Dollar Index continued its downward trend from 2025, officially breaking below the key 97.0 level and reaching a low of 95.5, marking a nearly four-year low since February 2022.
